NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free REGN Stock Alerts $896.82 +2.83 (+0.32%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$891.46▼$920.7350-Day Range$893.99▼$993.3552-Week Range$684.80▼$998.33Volume507,464 shsAverage Volume412,356 shsMarket Capitalization$98.43 billionP/E Ratio25.81Dividend YieldN/APrice Target$976.41 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside8.9% Upside$976.41 Price TargetShort InterestHealthy1.29% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.31Based on 24 Articles This WeekInsider TradingSelling Shares$13.12 M Sold Last QuarterProj. Earnings Growth3.99%From $38.59 to $40.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector246th out of 911 stocksPharmaceutical Preparations Industry99th out of 411 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 15 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.29% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 2.16%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 2.4 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Regeneron Pharmaceuticals this week, compared to 14 articles on an average week.Search InterestOnly 16 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat Follows19 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 12% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,124,641.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 3.99% in the coming year, from $38.59 to $40.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 25.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 25.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 269.39.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 3.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesApril 20, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Buy at StockNews.comApril 19, 2024 | finance.yahoo.comRegeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling CautionApril 20, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 19, 2024 | americanbankingnews.comUBS Group Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,099.00April 18, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) and Oragenics (NYSE:OGEN) Critical ReviewApril 17, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of InvestorsApril 17, 2024 | markets.businessinsider.comCantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN)April 17, 2024 | benzinga.comIf You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 TodayApril 20, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 16, 2024 | msn.comRegeneron to “vigorously defend” against DOJ on Eylea pricing complaintApril 16, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Receives "Neutral" Rating from Cantor FitzgeraldApril 15, 2024 | finance.yahoo.comRegeneron to defend against DOJ complaint on drug-price manipulationApril 15, 2024 | finance.yahoo.comUPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulationApril 15, 2024 | reuters.comRegeneron to defend US Justice Department's complaint on drug-pricing manipulationApril 14, 2024 | americanbankingnews.comBank of America Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $720.00April 14, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Lifted to "Strong-Buy" at StockNews.comApril 13, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 2.6%April 13, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)April 12, 2024 | markets.businessinsider.comBreaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their ViewsApril 11, 2024 | msn.comEye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye DrugApril 11, 2024 | investors.comAre Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?April 11, 2024 | msn.comUS accuses Regeneron of fraudulent price reporting for eye drugApril 11, 2024 | finance.yahoo.comDow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets RaisedApril 11, 2024 | finance.yahoo.comThese Stocks Are Moving the Most Today: CarMax, Fastenal, Alpine Immune, Nike, Robinhood, Constellation Brands, and MoreApril 11, 2024 | investopedia.comRegeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to WatchApril 11, 2024 | proactiveinvestors.comRegeneron Pharma falls after US government alleges fraudSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/02/2024Today4/20/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$976.41 High Stock Price Target$1,189.00 Low Stock Price Target$720.00 Potential Upside/Downside+8.9%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)$34.75 Trailing P/E Ratio25.81 Forward P/E Ratio23.24 P/E Growth2.6Net Income$3.95 billion Net Margins30.14% Pretax Margin32.01% Return on Equity17.61% Return on Assets13.76% Debt Debt-to-Equity Ratio0.10 Current Ratio5.69 Quick Ratio4.94 Sales & Book Value Annual Sales$13.12 billion Price / Sales7.50 Cash Flow$43.05 per share Price / Cash Flow20.83 Book Value$236.63 per share Price / Book3.79Miscellaneous Outstanding Shares109,760,000Free Float100,070,000Market Cap$98.43 billion OptionableOptionable Beta0.11 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $7MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $6.59MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.62MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $1.95MMs. Marion E. McCourt (Age 64)Executive Vice President of Commercial Comp: $1.5MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXBristol-Myers SquibbNYSE:BMYSanofiNASDAQ:SNYGSKNYSE:GSKZoetisNYSE:ZTSView All CompetitorsInsiders & InstitutionsMaryland State Retirement & Pension SystemBought 68 shares on 4/20/2024Ownership: 0.007%Mezzasalma Advisors LLCBought 33 shares on 4/20/2024Ownership: 0.002%FORVIS Wealth Advisors LLCSold 43 shares on 4/19/2024Ownership: 0.003%Valley National Advisers Inc.Bought 59 shares on 4/19/2024Ownership: 0.001%FCG Investment CoBought 31 shares on 4/19/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals has a diverse product portfolio, including innovative medicines like EYLEA and Dupixent, which have shown significant success in treating various diseases. The company's ongoing research and development efforts demonstrate a commitment to advancing healthcare solutions and potentially introducing new breakthrough treatments. Regeneron's collaboration with other pharmaceutical companies and research institutions enhances its capabilities for developing cutting-edge therapies and expanding its market reach. Recent positive regulatory approvals and clinical trial results have boosted investor confidence in the company's future growth prospects and revenue potential. Despite market fluctuations, Regeneron's stock price has shown resilience and maintained a relatively stable performance, offering investors a sense of security and potential long-term returns. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: Regeneron Pharmaceuticals faces intense competition in the biopharmaceutical industry, which could impact its market share and profitability over time. The company's heavy reliance on a few key products, such as EYLEA and Dupixent, for a significant portion of its revenue poses a risk in case of unexpected market changes or regulatory challenges. Fluctuations in research and development outcomes or delays in product launches could affect investor sentiment and lead to short-term volatility in the stock price. Regeneron's exposure to regulatory changes, pricing pressures, and intellectual property disputes within the healthcare sector may create uncertainties for investors regarding the company's future financial performance. Investing in biotechnology companies like Regeneron Pharmaceuticals involves inherent risks related to clinical trial failures, patent expirations, and market unpredictability, which could impact investment returns. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com. REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 20 brokerages have issued 12 month price targets for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $720.00 to $1,189.00. On average, they anticipate the company's stock price to reach $976.41 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2024? Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of the year. Since then, REGN stock has increased by 2.1% and is now trading at $896.82. View the best growth stocks for 2024 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our REGN earnings forecast. How can I listen to Regeneron Pharmaceuticals' earnings call? Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals's revenue was up .6% on a year-over-year basis. During the same period last year, the firm earned $10.96 earnings per share. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA) and American CenturyFocused Dynamic Growth ETF (FDG). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Global Assets Advisory LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Perpetual Ltd (0.08%), Allspring Global Investments Holdings LLC (0.05%), Atwood & Palmer Inc. (0.04%) and State of Michigan Retirement System (0.03%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.